Intervacc AB (publ) (STO:IVACC)

Market Cap	354.45M
Revenue (ttm)	11.79M
Net Income (ttm)	-75.52M
Shares Out	340.81M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	787,985
Average Volume	1,367,962
Open	1.070
Previous Close	1.070
Day's Range	0.995 - 1.070
52-Week Range	0.811 - 4.900
Beta	0.76
RSI	58.04
Earnings Date	Apr 4, 2025

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 15
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IVACC

Financial Performance

In 2024, Intervacc AB's revenue was 11.79 million, an increase of 46.84% compared to the previous year's 8.03 million. Losses were -75.52 million, -26.58% less than in 2023.